Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular and Translational Research in Cardiovascular Endocrinology, Cardio-Metabolic Diseases and...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular and Translational Research in Cardiovascular Endocrinology, Cardio-Metabolic Diseases and Non-alcoholic Fatty Liver Disease (NAFLD): 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1492

Special Issue Editors

Prof. Dr. Eva Kassi

E-Mail Website
Guest Editor
1. Department of Biochemistry, Medical School of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece
2. Unit of Endocrinology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, National & Kapodistrian University of Athens, 11527 Athens, Greece
Interests: women’s health; cardiovascular endocrinology; atherosclerosis; non-alcoholic fatty liver disease; endocrinology of adrenals; oestrogen receptor signalling; glucocorticoid receptor signalling; clock system in benign diseases and malignancies; ICI (immune checkpoint inhibitor)-related endocrinopathies; neuroendocrine tumours; vitamin D; calcium and phosphate metabolic disorders; gynaecological cancers
Special Issues, Collections and Topics in MDPI journals
Dr. Ioannis Kyrou

E-Mail
Guest Editor
1. Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
2. Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK
3. Centre for Sport, Exercise and Life Sciences, Research Institute for Health & Wellbeing, Coventry University, Coventry CV1 5FB, UK
4. Aston Medical School, College of Health and Life Sciences, Aston University, Birmingham B4 7ET, UK
5. Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, School of Food and Nutritional Sciences, Agricultural University of Athens, 11855 Athens, Greece
Interests: metabolism and energy homeostasis; nutrition; cardiovascular endocrinology; cardiovascular disease and atherosclerosis; exercise and health; COVID 19; epidemiology of non-communicable diseases and public health; obesity and obesity-related complications; type 2 diabetes; non-alcoholic fatty liver disease (NAFLD); endocrinology; endocrine-disrupting chemicals; polycystic ovary syndrome (PCOS); mental-health stress and the HPA axis
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Harpal S. Randeva

E-Mail Website
Guest Editor
1. Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
2. Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK
Interests: women’s health; endocrinology; gynaecological cancers; PCOS; metabolism; nutrition; diabetes; endocrine-disrupting chemicals (EDCs); links between obesity and cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of the first Special Issue “Molecular and Translational Research in Cardiovascular Endocrinology, Cardio-Metabolic Diseases and Non-alcoholic Fatty Liver Disease (NAFLD)”.

Cardiovascular tissues have been recognized as dynamic endocrine organs, with vital stimuli that affect the cardiovascular system acting in an endocrine manner through hormone receptors. Many of these signaling systems are complex and so interconnected, that, in many cases, the interlinked components are hard to separate.

Thus, cardiovascular disease, endocrinology, diabetes and metabolism represent closely linked disciplines, giving rise to the field of cardiovascular endocrinology. Moreover, pituitary, adrenal, parathyroid, thyroid and gender hormone excesses or deficiencies, as well as glucose and lipid metabolism disorders, may further impact on cardiovascular disease risk (e.g., directly or indirectly through atherosclerosis, heart failure and non-alcoholic fatty liver disease, NAFLD).

Despite the important advances in the field of cardiovascular endocrinology through recent molecular and translational research, there are still open issues regarding the underlying pathogenetic mechanisms, as well as the exact effects/impact of various interventions/treatments, such as lifestyle modification interventions (e.g., dietary and exercise interventions) or pharmacological therapies (e.g., anti-hypertensive, lipid-lowering, anti-diabetic drugs , etc.), which may target more than one aspects/factors of cardiometabolic diseases.

This Special Issue, which is edited by Prof E. Kassi, As. Prof. I. Kyrou and Prof. H.S. Randeva with the aid of our Topical Advisory Panel Member Dr. Narjes Nasiri-Ansari (Department of Biochemistry, Medical School, National and Kapodistrian University of Athens, Greece), focuses on cardiometabolic diseases and endocrine-related cardiovascular diseases, including atherosclerosis, heart failure, arterial hypertension, metabolic syndrome, obesity, diabetes mellitus, chronic kidney disease, NAFLD, and dyslipidemia, ranging from the molecular and cellular pathogenetic pathways to novel pharmacological and molecular targets for relevant treatments. Original research articles and reviews on these and related topics are welcomed in this Special Issue.

Prof. Dr. Eva Kassi
Dr. Ioannis Kyrou
Prof. Dr. Harpal S. Randeva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular endocrinology
  • atherosclerosis
  • coronary artery disease
  • endocrine hypertension
  • non-alcoholic fatty liver disease (NAFLD)
  • diabetes mellitus and obesity
  • metabolic syndrome
  • endothelial cells
  • vascular inflammation
  • antidiabetic drugs
  • antihypertensive treatments
  • lipid lowering treatments
  • lifestyle interventions
  • molecular targeted therapies
  • heart failure
  • chronic kidney disease

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 1118 KiB  
Article
Okinawa-Based Nordic Diet Decreases Plasma Levels of IAPP and IgA against IAPP Oligomers in Type 2 Diabetes Patients
by Dovilė Pocevičiūtė, Bodil Roth, Bodil Ohlsson and Malin Wennström
Int. J. Mol. Sci. 2024, 25(14), 7665; https://doi.org/10.3390/ijms25147665 - 12 Jul 2024
Viewed by 470
Abstract
Pancreas-derived islet amyloid polypeptide (IAPP) aggregates and deposits in the pancreas and periphery of Type 2 Diabetes (T2D) patients, contributing to diabetic complications. The excess IAPP can be removed by autoantibodies, and increased levels of immunoglobulin (Ig) G against IAPP have been reported [...] Read more.
Pancreas-derived islet amyloid polypeptide (IAPP) aggregates and deposits in the pancreas and periphery of Type 2 Diabetes (T2D) patients, contributing to diabetic complications. The excess IAPP can be removed by autoantibodies, and increased levels of immunoglobulin (Ig) G against IAPP have been reported in T2D patients. However, whether other Ig classes are also affected and if the levels can be managed is less known. This pre–post study examines IgA levels against IAPP oligomers (IAPPO-IgA) in T2D patients and assesses the impact of the Okinawa-based Nordic (O-BN) diet—a low-carbohydrate, high-fiber diet—on these levels after following the diet for 3 months. IAPP, IAPPO-IgA, and total IgA levels were measured in plasma and fecal samples from n = 30 T2D patients collected at baseline, after 3 months of diet, and after additional 4 months of unrestricted diets (a clinical follow-up). The IAPP and IAPPO-IgA levels were significantly lower after 3 months, with the latter also being significantly reduced at the clinical follow-up. The reduction in plasma IAPP and IAPPO-IgA levels correlated with reductions in plasma levels of metabolic and inflammatory markers. Hence, following the O-BN diet for at least 3 months is sufficient to reduce circulating IAPP and IAPPO-IgA levels, which may be principal in managing T2D. Full article
(This article belongs to the Special Issue Molecular and Translational Research in Cardiovascular Endocrinology, Cardio-Metabolic Diseases and Non-alcoholic Fatty Liver Disease (NAFLD): 2nd Edition)
►▼ Show Figures

Figure 1

16 pages, 1660 KiB  
Article
Lipid Emulsions Inhibit Labetalol-Induced Vasodilation in the Isolated Rat Aorta
by Soohee Lee, Kyeong-Eon Park, Yeran Hwang, Sungil Bae, Seong-Ho Ok, Seung-Hyun Ahn, Gyujin Sim, Hyun-Jin Kim, Seunghyeon Park and Ju-Tae Sohn
Int. J. Mol. Sci. 2024, 25(13), 7243; https://doi.org/10.3390/ijms25137243 - 30 Jun 2024
Viewed by 541
Abstract
Lipid emulsions are used as adjuvant drugs to alleviate intractable cardiovascular collapse induced by drug toxicity. We aimed to examine the effect of lipid emulsions on labetalol-induced vasodilation and the underlying mechanism in the isolated rat aorta. We studied the effects of endothelial [...] Read more.
Lipid emulsions are used as adjuvant drugs to alleviate intractable cardiovascular collapse induced by drug toxicity. We aimed to examine the effect of lipid emulsions on labetalol-induced vasodilation and the underlying mechanism in the isolated rat aorta. We studied the effects of endothelial denudation, NW-nitro-l-arginine methyl ester (l-NAME), calmidazolium, methylene blue, 1H-[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one (ODQ), and lipid emulsions on labetalol-induced vasodilation. We also evaluated the effects of lipid emulsions on cyclic guanosine monophosphate (cGMP) formation, endothelial nitric oxide synthase (eNOS) phosphorylation, and endothelial calcium levels induced by labetalol. Labetalol-induced vasodilation was higher in endothelium-intact aortas than that in endothelium-denuded aortas. l-NAME, calmidazolium, methylene blue, and ODQ inhibited labetalol-induced vasodilation in endothelium-intact aortas. Lipid emulsions inhibited labetalol-induced vasodilation in endothelium-intact and endothelium-denuded aortas. l-NAME, ODQ, and lipid emulsions inhibited labetalol-induced cGMP formation in endothelium-intact aortas. Lipid emulsions reversed the stimulatory and inhibitory eNOS (Ser1177 and Thr495) phosphorylation induced by labetalol in human umbilical vein endothelial cells and inhibited the labetalol-induced endothelial calcium increase. Moreover, it decreased labetalol concentration. These results suggest that lipid emulsions inhibit vasodilation induced by toxic doses of labetalol, which is mediated by the inhibition of endothelial nitric oxide release and reduction of labetalol concentration. Full article
(This article belongs to the Special Issue Molecular and Translational Research in Cardiovascular Endocrinology, Cardio-Metabolic Diseases and Non-alcoholic Fatty Liver Disease (NAFLD): 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1229 KiB  
Review
Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery
by Luis V. Herrera-Marcos, Jose M. Arbones-Mainar and Jesús Osada
Int. J. Mol. Sci. 2024, 25(15), 8285; https://doi.org/10.3390/ijms25158285 - 29 Jul 2024
Viewed by 328
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease characterized by the build-up of fat in the liver of individuals in the absence of alcohol consumption. This condition has become a burden in modern societies aggravated by the lack of appropriate predictive [...] Read more.
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease characterized by the build-up of fat in the liver of individuals in the absence of alcohol consumption. This condition has become a burden in modern societies aggravated by the lack of appropriate predictive biomarkers (other than liver biopsy). To better understand this disease and to find appropriate biomarkers, a new technology has emerged in the last two decades with the ability to explore the unmapped role of lipids in this disease: lipidomics. This technology, based on the combination of chromatography and mass spectrometry, has been extensively used to explore the lipid metabolism of NAFLD. In this review, we aim to summarize the knowledge gained through lipidomics assays exploring tissues, plasma, and lipoproteins from individuals with NAFLD. Our goal is to identify common features and active pathways that could facilitate the finding of a reliable biomarker from this field. The most frequent observation was a variable decrease (1–9%) in polyunsaturated fatty acids in phospholipids and non-esterified fatty acids in NAFLD patients, both in plasma and liver. Additionally, a reduction in phosphatidylcholines is a common feature in the liver. Due to the scarcity of studies, further research is needed to properly detect lipoprotein, plasma, and tissue lipid signatures of NAFLD etiologies, and NAFLD subtypes, and to define the relevance of this technology in disease management strategies in the push toward personalized medicine. Full article
(This article belongs to the Special Issue Molecular and Translational Research in Cardiovascular Endocrinology, Cardio-Metabolic Diseases and Non-alcoholic Fatty Liver Disease (NAFLD): 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop